Death from any cause · adults with acute spontaneous intracerebral haemorrhage
Summary of findings table ‐ Antifibrinolytic drug(s) showed no clear difference in death from any cause compared with placebo/open control (high certainty).
1 finding from 1 review
Mean quality of life ‐ health utility · adults with acute spontaneous intracerebral haemorrhage
1 finding from 1 review
Mood · adults with acute spontaneous intracerebral haemorrhage
1 finding from 1 review
Cognitive function · adults with acute spontaneous intracerebral haemorrhage
1 finding from 1 review
Death or dependence (mRS 4 to 6) at day 90 · adults with acute spontaneous intracerebral haemorrhage
Summary of findings table ‐ Antifibrinolytic drug(s) showed no clear difference in death or dependence (mRS 4–6) compared with placebo/open control (high certainty).
1 finding from 1 review
Intracerebral haemorrhage expansion by 24 hours · adults with acute spontaneous intracerebral haemorrhage
Summary of findings table ‐ Antifibrinolytic drug(s) leads to lower intracerebral haemorrhage expansion by 24 hours compared with placebo/open control (high certainty).
1 finding from 1 review
Incidence of postoperative instability · patients with lumbar stenosis
It is very uncertain whether summary of findings: split‐spinous process laminotomy changes incidence of postoperative instability compared with conventional laminectomy (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Incidence of perioperative complications · patients with lumbar stenosis
Summary of findings: split‐spinous process laminotomy showed no clear difference in incidence of perioperative complications compared with conventional laminectomy (low certainty).
1 finding from 1 review
Clinical relapse · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes clinical relapse (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
1 finding from 1 review
Maintenance of clinical remission · Patients with quiescent ulcerative colitis
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) showed no clear difference in maintenance of clinical remission (24 to 52 weeks) compared with 5‐ASA (mesalazine) (low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes withdrawal due to adverse events (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
1 finding from 1 review
Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with infective endocarditis due to penicillin‐susceptible Streptococci
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cure · people with infective endocarditis due to penicillin‐susceptible Streptococci
Beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) showed no clear difference in cure compared with beta‐lactam (ceftriaxone) (low certainty).
1 finding from 1 review
Adverse events · people with infective endocarditis due to penicillin‐susceptible Streptococci
It is very uncertain whether beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) changes adverse events compared with beta‐lactam (ceftriaxone) (very low certainty).
1 finding from 1 review
Congestive heart failure · people with infective endocarditis due to penicillin‐susceptible Streptococci
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Septic embolism · people with infective endocarditis due to penicillin‐susceptible Streptococci
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for cardiac surgical interventions · people with infective endocarditis due to penicillin‐susceptible Streptococci
It is very uncertain whether beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) changes need for cardiac surgical interventions compared with beta‐lactam (ceftriaxone) (very low certainty).
1 finding from 1 review